Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-07868489 · 2 trials · 2 indications
Part A
repeated doses
| Arm | Type | Description |
|---|---|---|
| Open Label | EXPERIMENTAL | Participants will receive subcutaneous doses of PF-07868489 every 4 weeks |
| PF-07868489 | EXPERIMENTAL | single subcutaneous injection (Part A); 6 subcutaneous injections at regular intervals (Part B) |
| Placebo | PLACEBO_COMPARATOR | single subcutaneous injection (Part A); 6 subcutaneous injections at regular intervals (Part B) |
| Name | Type | Description |
|---|---|---|
| PF-07868489 | DRUG | Participants will receive subcutaneous doses of PF-07868489 every 4 weeks |
| Placebo for PF-07868489 | DRUG | Placebo |
This study is seeking participants who are: * aged 18 years or older at screening of the previous study and completed the required treatment duration with PF-07868469 and other assessments at the end of that study. * willing and able to abide with all scheduled visits, treatment plan, laboratory te...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| United Therapeutics Corporation | UTHR | 5 | PHASE3 | Ralinepag |
| Merck & Co., Inc. | MRK | 6 | PHASE3 | Riociguat |
| Insmed Incorporated | INSM | 4 | PHASE3 | Treprostinil Palmitil |
| Johnson & Johnson | JNJ | 4 | PHASE3 | Selexipag |
| Liquidia Corporation | LQDA | 4 | PHASE3 | L606 |
| Tenax Therapeutics, Inc. | TENX | 3 | PHASE3 | TNX-103 |
| Inhibikase Therapeutics, Inc. | IKT | 1 | PHASE3 | IKT-001 |
| Gossamer Bio, Inc. | GOSS | 2 | PHASE3 | Seralutinib |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE2 | REGN13335 |
| Pfizer Inc. | PFE | 1 | PHASE2 | PF-07868489 |
| Tectonic Therapeutic Inc | TECX | 1 | PHASE2 | TX000045- Dose A, TX000045- Dose B |
| Abbott Laboratories | ABT | 1 | N/A | Undisclosed |
PF-07868489 is an investigational small molecule being developed for pulmonary hypertension and pulmonary arterial hypertension. It is currently in Phase 1 clinical development and is not approved by the FDA. The drug is being studied in healthy volunteers and in patients with pulmonary arterial hypertension.
PF-07868489 is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker symbol PFE. The company is conducting clinical trials to evaluate the drug's safety and efficacy in treating pulmonary hypertension and pulmonary arterial hypertension.
PF-07868489 is in Phase 1 clinical development. It is an investigational drug and has not received FDA approval. A Phase 1 study has been completed, and a Phase 2 study is active but not recruiting participants who previously took part in a PF-07868489 clinical trial.
PF-07868489 has one completed Phase 1 trial, NCT06137742, which enrolled 97 participants with pulmonary arterial hypertension and healthy volunteers. A Phase 2 trial, NCT07073820, is active but not recruiting, with 42 participants who previously completed a PF-07868489 study.
PF-07868489 is a unique investigational compound with no alternative names provided. It is being studied under its own identifier in clinical trials for pulmonary hypertension and pulmonary arterial hypertension. No other names for this drug have been disclosed.